API and Drug Master File Quality as Key Enablers of Pharmaceutical Manufacturing Localization in Saudi Arabia

References

[1] Turac I-R, Casian T, Iurian S, Porfire A, Iovanov R, Popa DE, Tomuță I. Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing. Pharmaceutics. 2026;18(8):935. https://doi.org/10.3390/pharmaceutics18080935.

[2] Saudi Food and Drug Authority (SFDA). Drug Master File (DMF): Guidance for Submission. Version 4.0. Riyadh: SFDA; 2020. https://www.sfda.gov.sa/sites/default/files/2020-08/DMF-GuidanceV4.pdf.

[3] Saudi Food and Drug Authority (SFDA). Good Manufacturing Practice (GMP) Guidelines. Riyadh: SFDA; 2023. https://beta.sfda.gov.sa/en/regulations/69378.

[4] Saudi Food and Drug Authority (SFDA). Data Requirements for Human Drugs Submission. Riyadh: SFDA; 2025; updated 2026. https://www.sfda.gov.sa/en/guide/19009.

[5] Saudi Food and Drug Authority (SFDA). Guidelines for Variation Requirements. Version 6.4. Riyadh: SFDA; 2026. https://www.sfda.gov.sa/sites/default/files/2026-03/Variation64.pdf.

[6] Saudi Vision 2030. National Industrial Development and Logistics Program: Delivery Plan 2021-2025. Riyadh: Kingdom of Saudi Arabia. https://www.vision2030.gov.sa/media/bsan2azp/2021-2025-national-industrial-development-and-logistics-program-delivery-plan-en.pdf.

[7] International Council for Harmonisation (ICH). Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Geneva: ICH; 2000. https://database.ich.org/sites/default/files/Q7%20Guideline.pdf.

[8] International Council for Harmonisation (ICH). ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023.

[9] International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System. Geneva: ICH; 2008.

[10] International Council for Harmonisation (ICH). ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). Geneva: ICH; 2012.

[11] International Council for Harmonisation (ICH). ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Geneva: ICH; 2019. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf.

[12] International Council for Harmonisation (ICH). M4: The Common Technical Document for the Registration of Pharmaceuticals for Human Use. Geneva: ICH; current version.

[13] US Food and Drug Administration. Drug Master Files: Guidance for Industry. Draft Guidance. Silver Spring, MD: FDA; 2019; current DMF program information available from FDA.

[14] European Medicines Agency. Guideline on Active Substance Master File Procedure. Revision 4. Amsterdam: EMA; 2019.

[15] European Directorate for the Quality of Medicines & HealthCare. CEP 2.0: Certificates of Suitability to the Monographs of the European Pharmacopoeia - revised dossier and lifecycle approach. Strasbourg: EDQM; implemented 2023.

[16] Tawfik EA, Tawfik AF, Alajmi AM, Badr MY, Al-Jedai A, Almozain NH, et al. Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. Saudi Pharm J. 2022;30(1):28-38. https://doi.org/10.1016/j.jsps.2021.12.002.

[17] Halwani AA, et al. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines. Saudi Pharm J. 2023;31(8):101674. https://doi.org/10.1016/j.jsps.2023.06.007.

[18] Alshehri S, et al. Current and future prospective of pharmaceutical manufacturing in Saudi Arabia. Saudi Pharm J. 2023;31(4):605-616. https://doi.org/10.1016/j.jsps.2023.03.001.

[19] Alhawassi TM, Abuelizz HA, Almetwazi M, Mahmoud MA, Alghamdi A, Alruthia YS, et al. Advancing pharmaceuticals and patient safety in Saudi Arabia: A 2030 vision initiative. Saudi Pharm J. 2018;26(1):71-74. https://doi.org/10.1016/j.jsps.2017.10.011.

[20] Marrone PV, et al. Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review. Economies. 2023;11(1):25. https://doi.org/10.3390/economies11010025.

[21] Grangeia HB, Silva C, Simões SP, Reis MS. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm. 2020;147:19-37. https://doi.org/10.1016/j.ejpb.2019.12.007.

[22] Kim EJ, Kim JH, Kim M, Jeong SH, Choi DH. Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification. Pharmaceutics. 2021;13(6):919. https://doi.org/10.3390/pharmaceutics13060919.

[23] Sagandira CR, Khasipo AZ, Sagandira MB, Watts P. Towards 4th industrial revolution efficient and sustainable continuous flow manufacturing of active pharmaceutical ingredients. React Chem Eng. 2022;7:214-244. https://doi.org/10.1039/D1RE00483B.

[24] Burange AS, Osman SM, Luque R. Understanding flow chemistry for the production of active pharmaceutical ingredients. iScience. 2022;25(3):103892. https://doi.org/10.1016/j.isci.2022.103892.

[25] Kumar V, et al. Active pharmaceutical ingredient (API) chemicals: a critical review of current biotechnological approaches. Bioengineered. 2022;13(2):4309-4327. https://doi.org/10.1080/21655979.2022.2031412.

[26] Cordeiro CF, et al. Impurities in Active Pharmaceutical Ingredients and Drug Products: A Critical Review. Crit Rev Anal Chem. 2026;56(1):55-75. https://doi.org/10.1080/10408347.2024.2384046.

[27] Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Characterizing Medicine Quality by Active Pharmaceutical Ingredient Levels: A Systematic Review and Meta-Analysis across Low- and Middle-Income Countries. Am J Trop Med Hyg. 2022;106(6):1778-1790. https://doi.org/10.4269/ajtmh.21-1123.

[28] Suda KJ, Tadrous M. Sum of the parts: Ensuring a resilient global drug supply chain. Infect Control Hosp Epidemiol. 2021. https://doi.org/10.1017/ice.2021.138.

[29] Costantino RC. The U.S. medicine chest: Understanding the U.S. pharmaceutical supply chain and the role of the pharmacist. J Am Pharm Assoc. 2021;61(1):e87-e92. https://doi.org/10.1016/j.japh.2020.07.018.

[30] Dispas A, Avohou HT, Lebrun P, Hubert P, Hubert C. Emerging analytical techniques for pharmaceutical quality control: Where are we in 2022? J Pharm Biomed Anal. 2022;221:115071. https://doi.org/10.1016/j.jpba.2022.115071.

@article{1722610,
      author = {Naseer Mitaigiri},
      title = {API and Drug Master File Quality as Key Enablers of Pharmaceutical Manufacturing Localization in Saudi Arabia},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {2},
      pages = {3154-3166},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1722610.pdf},
      abstract = {The extent to which Saudi Arabia's programme for localising its pharmaceutical industry relies on whether local manufacturers are able to obtain, comprehend, transfer, and consistently sustain control over high-quality active pharmaceutical ingredients (APIs) and the chemistry, manufacturing, and controls knowledge contained in Drug Master Files (DMFs) is examined in this review. Rather than viewing API quality and DMF quality as separate regulatory documents, the review treats them as linked industrial capabilities. It brings together recent work on pharmaceutical localisation, supply-chain resilience, Quality by Design, Process Analytical Technology, continuous manufacturing, and impurity control with the requirements of the Saudi Food and Drug Authority and the international ICH, FDA, EMA, and EDQM guidelines. The analysis states that localisation is successful when an API is not only in compliance with pharmacopeial standards at the time of release but is also backed by a reproducible process, scientifically justified specifications, qualified analytical methods, traceable impurity control, stability data, lifecycle change governance, and a current DMF that can be used to support regulatory assessments and technology transfer. In the context of Saudi Arabia, such attributes can help reduce uncertainty associated with technical transfers, shorten investigation periods, improve supplier qualification, strengthen local release testing, and enable effective post-approval change management. Two conceptual models are presented: an API-to-localisation value chain and a dual-engine readiness matrix that connects material quality with DMF maturity. The review concludes that policy on localisation should assess manufacturing readiness in terms of the depth of the quality system and the ability to transfer knowledge, rather than simply on the physical location of the final dosage-form production. The key priority actions should be benchmarking of DMF quality, the development of API suppliers on a risk-based basis, building up local analytical expertise, establishing structured lifecycle governance, using digital CMC data, and introducing incentives to encourage greater upstream manufacturing competence.},
      month = {August},
      doi = {https://doi.org/10.64388/IREV10I2-1722610}
  }